GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (STU:45O) » Definitions » Price-to-Free-Cash-Flow

Orgenesis (STU:45O) Price-to-Free-Cash-Flow : N/A (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Price-to-Free-Cash-Flow?

As of today (2024-04-27), Orgenesis's share price is €0.456. Orgenesis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.57. Hence, Orgenesis's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Orgenesis's Price-to-Free-Cash-Flow or its related term are showing as below:

STU:45O's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.52
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Orgenesis's Free Cash Flow per Share for the three months ended in Dec. 2023 was €-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-0.57.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 46.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 16.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -13.40% per year.

During the past 13 years, Orgenesis's highest 3-Year average Free Cash Flow per Share Growth Rate was 46.10% per year. The lowest was -519.30% per year. And the median was -26.80% per year.


Orgenesis Price-to-Free-Cash-Flow Historical Data

The historical data trend for Orgenesis's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Price-to-Free-Cash-Flow Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orgenesis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orgenesis's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Orgenesis's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Orgenesis's Price-to-Free-Cash-Flow falls into.



Orgenesis Price-to-Free-Cash-Flow Calculation

Orgenesis's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.456/-0.572
=N/A

Orgenesis's Share Price of today is €0.456.
Orgenesis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.57.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Orgenesis  (STU:45O) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Orgenesis Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Orgenesis's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (STU:45O) Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis (STU:45O) Headlines

No Headlines